IONIS ANGPTL3Rx

Drug Profile

IONIS ANGPTL3Rx

Alternative Names: ISIS-ANGPTL3Rx

Latest Information Update: 03 Mar 2017

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antihyperlipidaemics; Antisense oligonucleotides
  • Mechanism of Action ANGPTL3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dyslipidaemias

Most Recent Events

  • 02 Mar 2017 Discontinued - Phase-I for Dyslipidaemias (In volunteers) in USA (unspecified route) (Ionis Pharmaceuticals pipeline, March 2017)
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 23 Mar 2015 Efficacy and adverse event data from a phase I trial in healthy volunteers released by Isis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top